BioSpace News Archive

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced its participation in Bank of America Securities 2024 Healthcare Conference.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, reported financial results for the quarter ended March 31, 2024, and highlighted select corporate milestones and progress on its key clinical development programs.

Treos Bio, a clinical stage biotechnology company using data science and proprietary biomarkers to develop precision peptide immunotherapies, said investigators will present new results from a phase 2 trial of the company’s lead product candidate PolyPEPI1018 in combination with Roche’s PD-L1 inhibitor atezolizumab in patients with late-stage microsatellite stable metastatic colorectal cancer at the 2024 ASCO Annual Meeting.

Vericel Corporation reported financial results and business highlights for the first quarter ended March 31, 2024.

BioAtla, Inc. announced that the Company’s management will participate in a fireside chat and one-on-one investor meetings at the Citizens JMP Life Sciences Conference, to be held in New York, NY May 13-14, 2024.

Jnana Therapeutics announced that Joanne Kotz, Ph.D., Co-founder and Chief Executive Officer, will present a corporate overview at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 at 2:05 p.m. ET.

Keros Therapeutics, Inc. provided a business update and reported financial results for the quarter ended March 31, 2024.

Intra-Cellular Therapies, Inc., a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system disorders, announced that it will participate in two upcoming investor conferences.

60 Degrees Pharmaceuticals, Inc. announced today that a letter, titled Trial Planned to Evaluate Safety and Efficacy of Tafenoquine + Atovaquone/Azithromycin in Hospitalized Babesiosis Patients, authored by the Company’s Chief Executive Officer, Geoff Dow, PhD, has been published in the Journal of Infectious Diseases.

ArriVent BioPharma, Inc. reported financial results for the first quarter ended March 31, 2024, and highlighted recent Company progress.